重型再生障碍性贫血抗胸腺球蛋白治疗后伴垂体功能减退治疗研究

陈智; 戴铁颖; 林圣云<sup>*</sup>

引用本文:	陈智,戴铁颖,林圣云.重型再生障碍性贫血抗胸腺球蛋白治疗后伴垂体功能减退治疗研究[J].中国现代应用药学,2013,30(5):544-547.
	CHEN Zhi,DAI Tieying,LIN Shengyun.Case Report and Review: Hypopituitarism after the ATG Treatment for the Patient of Severe Aplastic Anemia[J].Chin J Mod Appl Pharm(中国现代应用药学),2013,30(5):544-547.

【打印本页】【HTML】【下载PDF全文】【查看/发表评论】【EndNote】【RefMan】【BibTex】

←前一篇|后一篇→

过刊浏览高级检索

本文已被：浏览 2390次下载 1992次	码上扫一扫！
分享到：微信更多字体:加大+\|默认\|缩小-
重型再生障碍性贫血抗胸腺球蛋白治疗后伴垂体功能减退治疗研究
陈智¹, 戴铁颖², 林圣云²
1.浙江中医药大学第一临床医学院，杭州 310006;2.浙江省中医院国家中医临床研究(血液病)基地，杭州 310006

摘要:

目的了解在使用ATG行强化免疫抑制治疗重型再障的过程中引起垂体功能减退的原因及相关并发症的防治。方法临床医师总结 1 例应用ATG引起垂体功能减退的诊治过程及对国内外文献进行查阅。结果 ATG可以引起垂体功能减退，应引起临床注意。结论在临床诊治重型再生障碍性贫血时，要特别注意潜在的并发症，从而降低治疗风险，提高疗效。

关键词: 重型再生障碍性贫血抗胸腺细胞球蛋白垂体功能减退

DOI：

分类号:

基金项目:浙江省中医药重大疾病科技创新平台科研专项(2009ZDJB01)；2011年浙江省科技厅创新团队(2011R09042-02)

Case Report and Review: Hypopituitarism after the ATG Treatment for the Patient of Severe Aplastic Anemia

CHEN Zhi¹, DAI Tieying², LIN Shengyun²

1.The First Clinical College of Zhejiang Chinese Medicine University, Hangzhou 310006, China;2.Zhejiang Provincial Hospital of Traditional Chinese Medicine, the National Chinese Medicine Clinical Research (Hematology) Base, Hangzhou 310006, China

Abstract:

OBJECTIVE To find out the cause of hypopituitarism induced by ATG in the process of intensive immunosuppressive therapy (IST) for severe aplastic anemia, and to prevent related complications. METHODS A case of hypopituitarism induced by ATG was chosen, which clinical physician participated in the whole treatment and literatures were reviewed. RESULTS ATG can induce hypopituitarism, which should bring enough attentions in clinical. CONCLUSION In the clinical diagnosis and treatment of severe aplastic anemia, we should pay more attention to the potential complications, so as to reduce the risk of treatment, improve the outcome of treatment.

Key words: aplastic anemia ATG hypopituitarism